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Abstract. In a previous study we observed that neu-
trophils respond with a rapid rise in [Ca2+]; during ad-
herence to cytokine-activated endothelial cells (EC),
caused by EC membrane-associated platelet-activating
factor (PAF). In the present study, we investigated
whether this form of PAF was important in neutro-
phil adherence and migration across monolayers of
rIL-lß- or ITNFa-prestimulated EC. PAF receptor
antagonists prevented neutrophil migration across
cytokine-pretreated EC by -60% (P < 0.005) without
interfering with the process of adherence. The antago-
nists WEB 2086 and L-652,731 had no effect on neu-
trophil migration across resting EC induced by formyl-
methionyl-leucyl-phenylalanine (FMLP) . A murine
T
RANSMIGRATION of neutrophils from the peripheral
circulation into inflammatory sitesrequires neutrophil
adherence to the endothelial cell lining of the blood
vessels. The CD18 complex proteins are: lymphocyte func-
tion-associated antigen-1 (LFA-1),' complement receptor 3
(CR3) or Mac-1, and glycoprotein 150,95 (p150,95). On neu-
trophils they are involved in both migration and adherence
(Anderson et al ., 1985 ; Harlan, 1985 ; Kuijpers and Roos,
1989). In these processes, endothelial intercellular adhesion
molecule-1 (ICAM-1) may function as a cellular ligand for
LFA-1 and CR3 (Rotplein et al., 1986 ; Diamond et al ., 1990;
Springer, 1990). Its expression can be increased by the in-
flammatory cytokines interleukin-1 (IL-1) and tumor necrosis
factor (TNF) (Dustin et al., 1986; Springer, 1990).
Several other adhesion molecules can play an accessory
role in the process of neutrophil adherence. The role of a
1.Abbreviations used in this paper: CR3, complement receptor 3; EC, en-
dothelial cells; ELAM-1, endothelialleukocyteadhesion molecule-l; FMLP,
formyl-leucyl-methionyl-phenylalanine ; HSA, human serum albumin;
ICAM-1, intercellular adhesion molecule-1; IL-1, interleukin-1; LAM-1, leu-
kocyte adhesion molecule-1; LFA-1, lymphocyte-function associated anti-
gen-1; MFI, mean fluorescence intensity; PAF, platelet-activating factor,
p150,95, (glyco)protein 150,95; rIL-1p, recombinant interleukin-lß; rIL-8,
recombinant interleukin-8; rTNFct, recombinant tumor necrosis fkctor-a;
TNF, tumor necrosis factor.
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anti-IL-8 antiserum was found to also partially inhibit
the neutrophil transmigration across cytokine-activated
EC. When the anti-IL-8 antiserum was used in combi-
nation with a PAF receptor antagonist, neutrophil
migration across cytokine-pretreated monolayers of
EC was completely prevented. During transmigration,
LAM-1 and CD44 on the neutrophils were down-
modulated; both WEB 2086 and anti-IL-8 antiserum
partially prevented this downmodulation caused by
cytokine-prestimulated EC.
Our results indicate that human neutrophils are acti-
vated and guided by EC-associated PAF and EC-derived
IL-8 during the in vitro diapedesis in between cytokine-
stimulated EC.
family of homologous lectin-like molecules in adherence is
well established. The human selectin family consists of
ELAM-1, GMP-140, and LAM-1 (Bevilacqua et al., 1989;
Johnston et al., 1989; Tedder et al., 1989). The endothelial
cell-specific adhesion molecule ELAM-1 is not expressed on
resting endothelium, but can be transiently induced by IL-1
and TNF with a peak after 4-6 h of cytokine treatment
(Bevilacqua et al., 1987; Leeuwenberg et al ., 1989; Lus-
cinskas et al., 1989). Upon stimulation of endothelial cells
with thrombin or histamine, a momentary upregulation of
GMP-140 takes place, as a result of the fusion of the intracel-
lular Weibel-Palade bodies with the plasma membrane.
GMP-140, together with enhanced expression of EC-asso-
ciated platelet-activating factor (PAF), causes transient ad-
herence of neutrophils to the endothelial cells (Gamble et
al ., 1990; Geng et al ., 1990; Lorant et al., 1991). Recent
evidence suggests a role for leukocyte adhesion molecule-1
(LAM-1) in the recruitment of leukocytes to inflammatory
lesions (Smith et al., 1991; Watson et al., 1991) . A role
for Mel-14 (the murine equivalent of the homing receptor
LAM-1; Camerini et al., 1990) to neutrophil migration was
demonstrated in a murine model: neutrophils present in the
tissues did not express Mel-14, in contrast to neutrophils in
the circulation (Jutila et al., 1989). The polymorphic inte-
gral membrane protein CD44 (also knownas the Hermes an-
tigen, ECMRIII, Hutch-1, or murine Pgp-1) is a distinct
565adhesion molecule. It recognizes hyaluronate (Aruffo et al.,
1990; Miyake et al ., 1990) and has been implicated in
processes such as lymphocyte binding to high endothelial
venules and matrix adhesion (Haynes et al ., 1989) .
We simulated the in vivo situation in an in vitro migration
assay using a two-compartment system. The transmigration
of neutrophils alonga chemotactic gradient of formyl-leucyl-
methionyl-phenylanine (FMLP) was compared with the
effect ofmigration through cytokine-prestimulated monolay-
ers of endothelial cells (EC) (Furie and McHugh, 1989;
Moser et al., 1989; Hakkert et al ., 1990). To a large extent
the enhanced neutrophil adherence to cytokine-prestimulated
EC can be ascribed to the expression of endothelial leuko-
cyte adhesion molecule-1 (ELAM-1) (Bevilacqua et al., 1987,
1989; Luscinskaset al., 1989; Hakkert et al., 1991), but the
reason for the directed migration of neutrophils across these
activated EC monolayers is unknown . We recently found en-
dothelial cell-associated PAF (or PAF-like) molecules to be
responsible for the rise of [Ca"]i in neutrophils during their
adherence to recombinant interleukin-1ß (rlL-1o)-prestimu-
lated EC. We assumed a functional role for this form of en-
dothelial PAF in guiding the neutrophils in between the EC
into the subendothelial area (Kuijpers et al., 1991x). In
the present study, we describe indeed a role for this form
of PAF on the surface expression of LAM-1, CD44, CDl lb,
and CD18 on neutrophils during the diapedesis across cyto-
kine-prestimulated monolayers. Moreover, both this EC-
associated form of PAF as well as the EC-derived chemoat-
tractant IL-8 is shown to be of major importance in the in
vitro neutrophil migration across cytokine-pretreated mono-
layers of human EC.
Materials andMethods
Reagents
FMLP and PAF were purchased from Sigma Chemical Co. (St. Louis,
MO). The PAF receptor antagonist WEB 2086 (Dent et al., 1989) was a
kindgift of Dr. H. Heuer (Boehringer Mannheim GmbH, Mannheim, Ger-
many); L-652,731 (Hwang et al., 1985) was obtained from Merck, Sharp
and Dohme Research Laboratories (Rahway, NJ). These agents were dis-
solved in DMSO at 1,000 times the final concentration for cell stimulation,
and were stored at -20°C. The engineered cDNA BBG44 coding for hu-
man IL-8 ([(Ser)-IL-8172) was purchased from British Biotechnology
Limited (Oxford, UK). The cDNA was expressed inEscherichiacoli strain
DH5a with the pMBLIl plasmid. Finally, 10 gg of highly purified (bioac-
tive) hrIL-8 was injected i.p. in a BALB/c mouse for the generation of
monoclonal anti-hrIL-8 antibodies. In a standard radioimmunoassay, the
(polyclonal) anti-IL-8 serum ((AL-8 serum) obtained from the same animal
was found to specifically recognize hrIL-8 up to a 106-fold dilution of the
antiserum (Margreet Hart, unpublished results).
The basal incubation mediumforcell suspensions consistedofa 1:1 mix-
ture of RPMI-1640 and Medium 199 (Gibco, Paisley, UK), supplemented
with 0.5% (wt/vol) human serum albumin (HSA).
Monoclonal Antibodies
The following mAbs were used: CD11b (CLB-B2 .12) (Van der Reijden et
al., 1983), CD18 (CLB-LFAl/1) (Miedema et al., 1984). CD32 (IV.3)
(Roosenfeld et al., 1985), CD44 (PI) (Pals et al., 1989), anti-HLA class-I
mAb W6/32, and anti-LAM-1 mAb Leu-8 (Kansas et al., 1985). The latter
mAb was obtained from Becton Dickinson & Co. (San Jose, CA).
GranulocyteIsolation
Blood was obtained from healthy volunteers. Granulocytes were purified
from the buffy coat of500 nil of blood anti-coagulated with 0.4% (wt/vol)
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trisodium citrate (pH 7.4) as described (Roos and De Boer, 1986). In short,
blood cells were separated by density gradient centrifugation over isotonic
Percoll with a specific gravity of 1.076 g/ml. The interphase, containing the
mononuclear cells, was removed. The pellet fraction, containing erythro-
cytes and granulocytes, was treated for 10 min with ice-cold isotonic
NH4C1 solution (155 mM HN4C1, 10 mM KHC03, 0.1 mM EDTA, pH
7.4) to lyse the erythrocytes. The remaining granulocytes were washed
twice in PBS containing HSA (0.5% wt/vol). Granulocytes were resus-
pended in the incubation medium at a final concentration of 1 x 106
cells/ml. Purity of the granulocytes was >98%, with >95% neutrophils.
LabelingofNeutrophils
Freshly purified neutrophils were radiolabeled with "Cr according to Gal-
lin et al. (1973) . Briefly, neutrophils (107 cells/ml) were incubated with 1
WCi S'Cr per 106 cells (sodium chromate, 200 to 500 Ci/g; New England
Nuclear, Boston, MA) inincubationmedium (containing 0.1% HSA instead
of0.5% HSA) at 37°C for 1 h under gently shaking conditions and subse-
quently washed. Viability after labeling was >95% .
Endothelial CellCulture
EC were isolated from human umbilical cord veins according to Jaffe et al.
(1973) with minor modifications (Willems etal., 1982). Cells were first cul-
tured in plastic flasks (80 cm2) precoated with fibronectin. The culture
medium consisted ofanequal mixtureofRPMI-1640and Medium 199, sup-
plemented with 20% (vol/vol) heat-inactivated human serum, penicillin
(100 U/ml; Gibco), streptomycin (100 pg/ml; Gibco), fungizone (2.5
jig/ml ; Gibco), andglutamine (2 mM). After one ortwopassageswith tryp-
sin/EDTA (Gibco), EC were subcultured to confluent monolayers on tissue
culture-treatedpolycarbonate membranes (8.0-Am pore size, 24-mm diam)
ofCostar Transwellcell culturechamber inserts (Costar, Cambridge, MA).
The filter chambers were precoated with fibronectin before EC were added
for further culturing. EC monolayers reached confluence in 3 to 4 d (as de-
terminedby May-Grünwald/Giemsa stainingor silver nitrate staining; Furie
et al., 1984). EC were held in culture for another 1 to 2 d to attain a real
tight (post-)confluent state, and were checked once again before use.
Pretreatment of EC monolayers with optimal concentrations of human
recombinant IL-lß (10 U/ml) or TNFci (50 ng/ml) (see below) did not
change the state of confluence.
Inununoperoxidase staining for von Willebrand Factor was homoge-
neous in the cultures. Volumes of the lower and upper chambers were 2.6
and 1.5 ml, respectively.
AdherenceandMigrationAssay
The confluent monolayers were washed twicewith basal incubation medium
prewarmed to 37°C. Prewarmed incubation medium with or without an op-
timal amount ofthe chemoattractant FMLP (10 nM) was added tothe lower
chambers. S'Cr-labeled neutrophils (1 x 106 cells/nil), prewarmed for 10
min at 37°C, were then added to the upper compartments. In some experi-
ments, neutrophils were preincubated for 10 min with PAF receptor antago-
nists WEB 2086 (10 uM) or L-652,731 (100 pM) before use. The same
amount of DMSO was added to the control experiments (which had no
significant effect on adherence, transmigration, or surface antigen modula-
tion). The PAF receptor antagonists remained present during the migration
assay. The EC were preincubated for 20 min with the anti-IL-8 antiserum
(complement inactivated bya 56°C treatment for45 min), before theneutro-
phils were added. The anti-IL-8 antiserum remained present during the as-
say. There was no significant effect on adherence, transmigration, or surface
antigen modulation observed with preimmune, complement-inactivated se-
rum of BALB/c mice (tested at 1:100 diluted).
The chamber plates were then incubated at 37°C ina 5% C02 incubator
for 30 min (or other times as indicated). After 30 min, neutrophil fractions
were collected, and diluted with a fixed amount ofincubation medium used
to wash the upper and lower chambers. Radioactivity was determined in
three cell fractions: luminal, abluminal, and "adhering cell" fraction (i.e.,
the complete membrane, carefully cut out of its container) . Recovery was
always >92 % . Adhesion was measured as radioactivity found in the "mem-
brane fraction" and migration was measured as radioactivity found in the
abluminal fraction (lower compartment). The results were expressed as per-
centage of radioactivity added to the chambers.
In the experiments for surface antigen expression (see below), neutro-
phils were used that had not been radiolabeled but had undergone exactly
the same procedure as radiolabeled cells (i.e., incubation for 1 h at 37°C,
washing, etc.). The transmigration experiments were usually performed
566simultaneously with radioactive neutrophils and with non-radioactive neu-
trophils, for an optimal comparison of adherence/diapedesis and the effects
of migration on surface antigen expression.
EC monolayers were pretreated with optimal concentrations of human
recombinant IL-10 (rIL-lß, 10 U/ml) or TNFa (rTNF(x, 50 ng/ml). The
cytokine was left for 4 h with the cells followed by extensive washing ofthe
monolayer with prewarmed incubation medium before use. Human rIL-lß
was a kind gift of Dr. P. T. Lomedico (Hoffmann-La Roches, Nutley, NJ).
Human rTNFce was a gift of Dr. A. Creasy (Cetus, Oakland, CA).
PAFMeasurement:Extraction andBioassay
Confluent monolayers ofhuman EC cultured in Petri dishes were maximally
stimulated either with thrombin (2 U/ml) for 7 min, or with rIL-lß for 4
and 24 h. Lipid extraction was performed according to Bligh and Dyer
(1959). After rapid removal of the supernatant, PAF biosynthesis in the
monolayers was blocked by addition of 1 ml ofmethanol containing 50 mM
acetic acid. EC were harvested with a rubber scraper. The Petri dishes were
rinsed with 2 nil ofacidified methanol, and this was added to the cells. Then
2 .5 ml of chloroform was added to the cell suspension and the mixture was
vortexed for 3 min. Another 2.5 ml of chloroform was added and the mix-
ture was again vortexed, followed by the addition of 2.5 rrd of distilled
H2O. This mixture was again vortexed (30 s), the organic phase was col-
lectedand evaporated undernitrogen. HPLC purification wasperformed es-
sentially as described by Remy et al. (1989). PAF volume andretentiontime
were determined with standard [3H]-PAF. The fractions corresponding to
PAF were subsequently collected and evaporated under nitrogen.
The quantification ofbiologically active PAF was performed according
toBenveniste et al . (1972). In short, rabbit blood anti-coagulatedwith 0.4%
trisodium citrate (wt/vol) was centrifuged at 200 g for 15 min. The platelet-
rich plasma was collected. Then platelets were centrifuged at 1,500 g for
15 min, washed twice and resuspended in a buffer containing 137 mM
NaCl, 2.6 mM KCI, 1 MM MgC12, 1.3 mM CaC12, 12 mM NaHC03, 0.1%
(wt/vol) glucose and 0.25% (wt/vol) gelatine (pH 7.4). Aggregation was
performed in a standard aggregometer under continuous stirring at 37°C.
In a cuvette, 1.6 ml of the buffer, 25 Al of an indomethacin solution (1 .5
mg/ml ethanol), and 400 wl of the platelet suspension were mixed and
prewarmed for 5 min. Then 50 Wl of sample PAF was added and compared
with the effect ofstandard PAR The amount of endothelial PAF was calcu-
lated from the PAF standard aggregation curve.
WEB 2086 and L-652,731 specifically inhibited the standard PAF activ-
ity and the EC-derived PAF activity on rabbit platelets (not shown). These
PAF receptor antagonists also inhibited other biological effectsof PAF, such
as neutrophil aggregation, elevation of neutrophil [Ca2+]; and priming of
neutrophil oxidase activity. In contrast, these antagonists did not influence
similar effects of FMLP, recombinant C5a or IL-8 on neutrophils. WEB
2086 was found to bind only to membranes of COS-7 cells specifically
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transfected with the cloned PAF receptor (Honda etal., 1991). Thus, WEB
2086 and L652,731 appear to be both effective and specific PAF receptor
antagonists (see also Kuijpers et al ., 1991x). In addition, the neutrophil-
activating lipid associated with the EC plasma membrane after treatment
of the EC with thrombin (Lorant et al., 1991), or rIL-1/i (Kuijpers et al .,
1991x) appears to be PAF.
Determination ofSurfaceAntigen Expression
Neutrophils in suspension or collected from either the upper or lower com-
partment were used for indirect immunofluorescence and flowcytometric
analysis on a FACScan (a registered trademark of Becton Dickinson & Co.,
Mountain View, CA) . The effects ofFMLP(10 nM)-dependent transmigra-
tion were compared with the influence of FMLP (10 nM) on neutrophils
held in suspension at 37°C during the same time needed forthe transmigra-
tion assay (i.e., 30 min, see above). The collected neutrophils were washed
with ice-cold PBS and subsequently incubated with primary antibody for
30 min at 4°C. Thereafter, the cells were washed twice in excess of ice-cold
PBS, and the procedure was repeated with FITC-labeled goat-anti-mouse-
Ig for another 30 min at 4°C. Neutrophils were distinguished by for-
ward-sideward scatter pattern. Data were collected from 10,000 cells and
are represented as Mean Fluorescence Intensity (MFI). No subpopulations
were observed.
StatisticalAnalysis
For statistical analysis t tests were performed. P values >0.05 were consid-
ered NS.
Results
Adhesion andMigration
Previous studies have already shown a transmigration of neu-
trophils across EC monolayers prestimulated for 4 to 8 h
with IL-1 (Furie and McHugh, 1989 ; Moser et al., 1989;
Hakkert et al ., 1990). However, the mechanism underlying
this process remained unexplained. We adopted a chamber
system with confluent monolayers of EC cultured on top of
microporous membranes to simultaneously study the pro-
cess of adherence and migration. In the presence of a
chemotactic amount of FMLP (10-8 M) in the lower com-
partment, the optimal adherence ofneutrophils to the resting
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Figure 1. Neutrophil adherence to and migration across confluent monolayers of EC. At various times both adherence and migration were
determined. (A) Neutrophils were attracted to the lower chamber by a chemotactic amount of FMLP (10-8 M) . (B) The EC were pre-
stimulated for 4 h with rIL-1/3. Results expressed as the mean f SEM for three experiments on different occasions. (m) Adherence; (o)
migration.EC monolayers was observed at 10-15 min after the neutro-
phils had been added to the upper compartment (Fig. 1 A).
On the other hand, FMLP-induced migration continued to
increase (Fig. 1 A). Experiments with rIL-1/3-pretreated
monolayers showed optimal adherence between 15 and 30
min and considerable neutrophil migration at about 30 min
(Fig. 1 B). Adherence of neutrophils to recombinant tumor
necrosis factor-a (rTNFa)-pretreated EC also reached its
optimum at 30 min (not shown). In all further experiments,
we therefore allowed neutrophils to adhere and migrate for
30 min in either the FMLP- or cytokine-dependent assays.
Lysis of cells during the migration assay was negligible
(LDH release <5 %, not shown).
Our previous experiments (Kuijpers et al., 1991x) had dis-
closed that IL-1 treatment of EC monolayers led to the gener-
ation of an EC-associated factor able to induce a rise of
[Cal+]; in adhering neutrophils. For the detection of [Cal+];
changes we used suspended EC, non-enzymatically detached
with EDTA-containing medium. This rise of [Ca2+]; in ad-
hering neutrophils was caused by endothelial PAF, as demon-
strated by the fact that: (a) the use of PAF receptor antago-
nists; (b) neutrophilic PAF receptor desensitization ; or (c)
PLA2 inhibitors (mepacrine and p-bromophenacylbromide)
prevented the rise of [Ca2+]; in adhering neutrophils. Adher-
ence was insignificantly affected under these conditions.
Washing of the cytokine-activated EC did not diminish their
capacity to invoke the [Ca2+]; changes, unless the EC were
washed in medium containing defatted albumin, known to
remove polar substances such as PAR The endothelium-
derived PAF was not released into the medium, either in the
absence or the presence ofadhering neutrophils (Kuijpers et
al., 1991x) . As shown here for rIL-lß, PAF was newly syn-
thesized upon cytokine treatment, although less than observed
upon optimal activation of EC monolayers with thrombin
(Table I) . PAF expression upon EC treatment with rIL-lß (or
rTNFce) followed the same kinetics as ELAM-1 expression,
i.e., with a peak at 4-6 h after cytokine addition (Kuijpers
et al ., 1991x; data not shown).
The percentage of neutrophils migrating into the lower,
FMLP-containing chamber was high. PAF receptor antago-
nists (WEB 2086 or L-652,731 did not affect the FMLP-
dependent migration (Fig. 2). When EC were prestimulated
for about4 h with rIL-lß or rTNFa and subsequently washed
several times, neutrophils were found to adhere avidly (Fig.
2) . Migration across the monolayer into the lower chamber
was also considerable (Fig. 2). The PAF receptorantagonists
significantly inhibited the neutrophil migration under these
conditions (P < 0.005), without affecting adherence. How-
ever, titration curves reproducibly showed that the PAF
Table 1. Endothelial De Novo Synthesis of
PAF upon Stimulation
Addition
No stimulus
rIL-lß (10 U/ml)
thrombin (2 U/ml)
EC were stimulated with rIL-lß (10 U/ml) for 4 h, or with thrombin (2 U/ml)
for 7 min, i.e., the time point at which the endothelial PAF synthesis was found
to be maximal. Activation of the EC was stopped with methanol (see Materials
and Methods). Results are expressed as the mean for three different experi-
ments in duplicate.
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0
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0.30 x 10- '2
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Figure 2. Neutrophil adherence to and migration across confluent
monolayers of EC either resting or prestimulated by rIL-lß or
rTNFa for 4 h. In case of resting monolayers of EC, neutrophils
were attracted to the lower chamber by a chemotactic amount of
FMLP (10-sM) . The PAF receptor antagonists WEB2086 (10 AM)
or L-652,731(100 AM) significantly inhibited neutrophilmigration
across EC pretreated with rIL-lß or rTNFa (P < 0.005). Results
expressed as the mean t SEM for six to ten experiments on differ-
ent occasions. (m) Adherence at 30 min; (o) migration at 30 min.
receptor antagonists did not completely block neutrophil
migration, as shown here for WEB 2086 (Fig. 3).
The potential role of IL-8 (Baggiolini et al., 1989), a
neutrophil agonistic stimulus generated by (e.g.) cytokine-
treated EC (Wheeler et al., 1988; Schr6der and Christophers,
1989), was also investigated. We used a 1:1,000 dilution of
a murine anti-IL-8 antiserum; this completely prevented
neutrophil migration along a gradient of rIL-8 (10-8 M) (not
WEB 2086, 1 PM
WEB 2086, 3 PIA
WEB 2086, 10 PM
WEB 2086, 30 uM
568
EC (IL-1)
0 10 20 30 40 50
Figure 3. Neutrophil adherence to and migration across rIL-10-
prestimulated EC in the presence ofdifferent concentrations of the
PAF receptor antagonist WEB 2086. Results are expressed as the
mean f SEM for three experiments on different occasions. (m)
Adherence at 30 min; (o) migration at 30 min.Table II. Role of Endothelial PAF
and IL-8 in the NeutrophilAdherence to, and
Migration across, Monolayers of EC
Themurine anti-IL-8 antiserum (aIL-8) was used at a fully inhibitory dilution
of 1 :1,000. The PAF receptor antagonist WEB 2086 wasused at a concentra-
tion of 10 pM. The reagents remained present during the transmigration. Nor-
mal mouse serum did not have any effect. Results are expressed as mean ±
SEM of three to six separate experiments.
shown) . Whereas the FMLP-dependent transmigration was
unaffected in the presence of the anti-IL-8 antiserum, the
neutrophil migration across cytokine-activated EC was in-
hibited by -60% (Table II). In combination with PAF recep-
tor antagonists, transmigration was totally blocked . However,
in the presence of WEB 2086 and the anti-IL-8 antiserum,
neutrophils still migrated across the activated EC when FMLP
was included in the lower chamber (43% ± 8.4 %, mean ±
SEM, n = 3 at 30 min).
Fixation of monolayers of cytokine-activated EC with PFA
(1%, wt/vol) made the EC impermeable to the neutrophils
(Fig. 4), unless the exogenous chemoattractant FMLP was
added to the lowercompartment. The number ofneutrophils
adhering the cytokine-activated EC was almost unchanged,
indicating that PFA-sensitive products of EC (primarily)
determine the neutrophil migration across cytokine-acti-
vated EC.
Changes in Neutrophil Surface Antigen Expression
We further investigated whether the change in surface ex-
pression ofthe adhesion molecules CDllb/CD18 and LAM-1
on transmigrating neutrophils (Kuijpers et al., 1992), was a
result of the action of PAF or IL-8. Hence, migrated neutro-
phils in the lowercompartment were compared with the neu-
trophils in the upper compartment. The effects of FMLP
(10-5 M) present in the lower compartment of the two
chamber system were related to the changes induced by an
identical concentration ofFMLP on neutrophils held in sus-
pension during the same period. In suspension, the expres-
sion of CD1lb (the ot-chain ofCR3), and CD18 (the common
ß-chain of LFA-1, CR3 and p150,95) was significantly in-
creased by FMLP, whereas the expression of LAM-1 and
CD44 significantly decreased (Table III). The expression of
CD32 (FcyRII) (Table III) or HLA class I (not shown) did
not change under these conditions.
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Figure 4. Neutrophil adherence to and migration across mildly
fixedconfluent monolayers ofeither resting EC or EC prestimulated
for 4 h with rIL-1ß or rTNFci before fixation . Monolayers were
fixed with prewarmed PEN 1% (wt/vol) in basal incubation me-
dium for 10 min in the incubator. Thereafter, the monolayers were
thoroughly washed four times by excess of prewarmed incubation
medium before further use. Results are expressed as the mean ±
SEM of four different experiments. (m) Adherence at 30 min; (o)
migration at 30 min.
The neutrophils that had migrated showed an identical
modulation ofthese surface antigens (Table III) . The neutro-
phils in the upper compartment appeared to be affected as
well, as indicated by the significantly changed expression
(p < 0.05) of CDllb, CD18, CD44, and LAM-1. These last
effects can be ascribed to FMLP that diffuses from the lower
compartment into the upper chamber. Neutrophils added to
the upper chamber in the absence ofFMLP did not show the
changes in surface antigen expression .
The neutrophils that had migrated across rIL-1/3-prestim-
ulated EC showed similar changes in surface antigen ex-
pression (Table IV) . The relatively larger increases in CD18
expression as compared to CDllb on transmigrated neutro-
Table III. Changes in Surface Antigen Expression on
Neutrophils in Suspension orMigrated across EC
Monolayers along a Gradient ofFMLP
Neutrophils in suspension were activated with FMLP (10-e M) for the same
period (30 min) during which migration took place. Results are expressed as
MFI ± SEM for experiments on six to ten different occasions. The surface an-
tigen expression of untreated neutrophils in suspension was compared with the
expression of the same antigen on FMLP-treated neutrophils in suspension.
Similarly, luminal neutrophils were compared with abluminal (transmigrated)
neutrophils. Anti-TNP was used as an isotype-matched "control" antibody.
Data marked by an asterisk (*) were significantly different (P < 0.05).
Addition Adherence Transmigration
(%) (%)
2 ± 1 .1 2 ± 0.8
FMLP (10 nM) 12 ± 2.7 35 ± 4.5
aIL-8 12 ± 3.2 36 ± 5.6
WEB 2086 13 ± 4.2 37 ± 6.2
aIL-8 + WEB 2086 12 ± 3.8 35 ± 4.9
EC (IL-1) 36 ± 3.4 29 ± 2.7
aIL-8 38 ± 5 .1 12 ± 6.2 (P < 0.005)
WEB 2086 35 ± 4.8 13 ± 4.6 (P < 0.005)
aIL-8 + WEB 2086 37 ± 5 .4 3 ± 2.9 (P < 0.001)
EC (TNF) 50 ± 7.4 25 ± 4.5
aIL-8 49 ± 5.1 11 ± 3 .9 (P < 0.005)
WEB 2086 49 ± 8.8 10 ± 6.1 (P < 0.005)
aIL-8 + WEB 2086 47 ± 9.3 4 ± 2 .6 (P < 0.001)
Control (susp) FMLP (susp) Luminal Abluminal
Control 10±0.3 10±0.5 10±0.4 10 ± 0.3
CD 11b 289 ± 24.8 455 ± 32.6* 389 ± 47.6 528 ± 57.7*
CD18 61±18.4 193±24.1* 89±9.7 208 ± 40.1
CD32 108 ± 12.1 101 ± 6.8 115 ± 11 .2 112 ± 5.7
CD44 368 ± 13 .7 275 ± 15 .9* 348 ± 16.4 299 ± 15 .4*
LAM-1 121 ± 10.9 17 ± 2 .0* 41 ± 6 .5 15 ± 1 .8*Table IV. Changes in Surface Antigen Expression on Neutrophils Migrated across EC Monolayers
Prestimulated for 4 h with rIL-1ß
Results are expressed as MFI ± SEM for experiments on four to ten different occasions. The surface antigen expression on luminal neutrophils was compared
with the expression of the same antigen on abluminal (Transmigrated) neutrophils. The PAF receptor antagonist WEB 2086 was present at 10 WM . L-652, 731
was not tested in this set of experiments. The murine anti-IL-8 antiserum (aIL-8) was used at a fully inhibitory dilution of 1 :1,000. Data marked by an asterisk
(*) were significantly different (P < 0.05).
phils (Tables III and IV) can be explained by the simultane-
ous upregulation of the a-subunit CDl lc of p150,95 (CDllc/
CD18), whereas LFA-1 (CDlla/CD18) remained unchanged
(not shown) .
In the presence ofthe PAF receptor antagonist WEB 2086,
the abluminal transmigrated neutrophils showed a strongly
reduced up-regulation of the surface antigens CDllb and
CD18 compared to neutrophils at the luminal side. WEB
2086 apparently interfered with the (extent of) modulation
of surface antigen expression, as was also demonstrated by
the significantly reduced down-modulation of LAM-1 and
CD44 during diapedesis (P < 0.05). However, the neutro-
phils still displayed a diminishedexpression of LAM-1 under
these conditions of cytokine-activated EC (Table IV) as com-
pared to control neutrophils in suspension (Table III) .
Results obtained with neutrophils migrated across rTNFa-
pretreated EC monolayers were identical (not shown) . More-
over, the effects on surface antigen expression observed in
the presence of the anti-IL-8 antiserum, gave similar results
as noted with WEB 2086 (Table IV) . No effect on the surface
antigen expression was observed with WEB 2086 or anti-IL-8
antiserum when the neutrophils had migrated to FMLP (10
nM), or when suspended neutrophils were activated with
FMLP (1 nM) (not shown) .
Discussion
The entry of neutrophils into inflamed tissues is a prerequi-
site for an early and adequate elimination of invading
microorganisms. Neutrophil adherence to the vascular cell
lining is followed by diapedesis, a process of complex move-
ments of the neutrophils between the EC into the suben-
dothelial area. The cellular movements are fueled by the
presence of a chemotactic gradient of mediators generated
at the site of inflammation, e.g., bacterial FMLP-like pep-
tides, lipid-derived mediators such as PAF and leukotrienes,
or chemotactic cytokines (Snyder, 1987; Williams and Higgs,
1988; Baggiolini et al., 1989; Prescott et al ., 1990). How-
ever, without proof of such a gradient, in case of IL-1-pre-
stimulated endothelium, neutrophil migration across these
EC monolayershas also been established (Furie and McHugh,
1989; Moser et al., 1989; Hakkert et al., 1990, 1991).
Pretreatment of EC with IL-1 induced the synthesis ofPAF
(Table I), as was reported before (Bussolino et al., 1986;
Breviario et al., 1988). For unknown reasons, Zavoico et al.
(1989) did not find this cytokine-induced PAF generation in
The Journal of Cell Biology, Volume 117, 1992
EC. The form of PAF we measure is strictly membrane-
associated and induces rapid rises of [Caz+], in neutrophils
adhering to rIL-lß-prestimulated EC, yet without exerting
much influence on adherence as such (Kuijpers et al .,
1991x). The present study shows that an EC-associated,
PAF-dependent mechanism is operative in neutrophil pas-
sage across the rIL-lß-pretreated EC monolayers. The same
appeared to be true in case of ÍTNFa-pretreated EC mono-
layers. The specific PAF receptor antagonists WEB 2086 and
L-652,731 did not affect adherence significantly, whereas
neutrophil migration across the cytokine-activated EC mono-
layers was inhibited by -60% (Fig. 2 and Table II) . In con-
trast, blockade of the PAF receptor does inhibit the adher-
ence of neutrophils to thrombin or histamine-treated EC
(Lorant et al ., 1991), probably because these EC do not ex-
press ELAM-1. The FMLP-driven migration of neutrophils
across resting untreated EC was not influenced by the PAF
receptor antagonists.
PAF was not the only mediator involved in the neutrophil
migration, as indicated by the incomplete reduction ofdiape-
desis at high concentrations of WEB 2086 (Fig. 3). The sec-
ond mechanism involved in neutrophil migration across
cytokine-activated EC proved to be the neutrophil agonistic
stimulus IL-8, as can be concluded from the preferential in-
terference in this migration by a specific and highly potent
anti-IL-8 antiserum (Table II). Huber et al. (1991) have re-
cently reported that neutrophil migration was blocked by
75-80% in the presence of anti-IL-8. Neutrophil adherence
to IL-10-pretreated EC was almost completely prevented by
anti-IL-8 as well, suggesting a very limited contribution of
ELAM-1. In contrast, our inhibitory anti-IL-8 antiserum
resulted in -60% inhibition of the migration without any
effect on adherence (Table II). As expected under these con-
ditions, neutrophil adherence was strongly reduced by anti-
ELAM-1 mAb (not shown). Binding of neutrophils to
ELAM-1 occurs in a very avid way, as also indicated by the
CD18 independency in adherence under flow conditions
(Lawrence et al., 1990). Whereas we cultured EC on
fibronectin for ti5 d before use, Huber et al . (1991) have used
EC cultured for 21 d on collagen matrices. It is not known
to which extent PAF or ELAM-1 can be induced in these
long-term cultures upon cytokine or LPS activation. The
difference in EC cultures may thus explain the prominent
role for IL-8 in their migration system. In our system the
contribution of endothelial IL-8 and PAF is more balanced.
Whereas soluble IL-8 has been reported to down-regulate
570
Luminal
-
Abluminal
-
Luminal
+ WEB
Abluminal
+ WEB
Luminal
+ aIL-8
Abluminal
+ aIL-8
Control 10±0.3 10±0.5 10±0.4 10±0.3 10±0.5 10±0.4
CDllb 321 ± 75.2 465 ± 34.3* 304 ± 68.3 342 ± 87.4 298 ± 66.6 339 ± 75.9
CD18 97 ± 24.1 201 ± 31.2* 77 ± 14.5 138 ± 17 .9* 82 ± 20.7 119 ± 33 .1
CD32 119 ± 13.3 111 ± 12.8 107 ± 7 .9 110 ± 15 .1 111 ± 14.5 115 ± 16.4
CD44 343 ± 18.4 275 ± 7.6* 350 ± 16.4 317 ± 46.2 377 ± 33 .3 311 ± 50.0
LAM-1 83 ± 11.6 18 ± 2.2* 85 ± 11 .3 73 ± 11 .8 90 ± 22 .0 69 ± 16.9neutrophil adherence to cytokine-activated EC (Wheeler et
al., 1988; Gimbrone et al., 1989), the pro-inflammatory re-
sponse predominates in our system. This might be explained
by the fact that all soluble IL-8 present was rinsed away be-
fore the addition of neutrophils to the upper compartment
(Wheeler et al., 1988). It is as yet unclear whether the IL-8
is localized underneaththe EC from where it slowly diffuses,
thereby creating a kind ofchemotactic gradient. These issues
of localization and the precise time course will be further in-
vestigated .
We observed a significant down-modulation of CD44 and
LAM-1, in the FMLP-dependent transmigration as well as in
the migration across cytokine-treated EC (Tables III and
IV) . The down-modulation of these antigens in the FMLP-
driven migration is a result ofthe neutrophil activation by the
chemotactic mediator itself (Table II). Both molecules are
down-modulated by shedding. Shedding of CD44 is the re-
sult of a DFP-sensitive proteolytic activity. CD44 can be im-
munoprecipitated from the supernatant of FMLP- or PMA-
activated neutrophils, with a slightly reduced molecular
weight compared to intact CD44 from neutrophil lysates
(Kuijpers, T. W., and M . Hoogerwerf, unpublished observa-
tions) . The extreme sensitivity of LAM-1 for shedding from
neutrophils upon their activation was previously demon-
strated by Jutila et al. (1990). The down-modulation of
LAM-1 on neutrophils observed after migration across
cytokine-treated EC was partly prevented by WEB 2086 or
the anti-IL-8 antiserum (Table IV) . Probably, shedding of
these proteins is the result ofa combined PAF/IL-8 activation
of the neutrophils.
In another study (Kuijpers et al., 1992), we have found
that neutrophils upregulate not only CDl lb and CD18 during
transmigration but also CD45 and CD67, indicating that fu-
sion of the specific (and tertiary) granules with the plasma
membrane takes place during this process. This was found
both with FMLP-induced diapedesis and with diapedesis
across IL-10-treated EC. In contrast, CD63 was not upregu-
lated, indicating that fusion of azurophil granules does not
occur under these conditions (Kuijpers et al., 1991b). How-
ever, pretreatment of the neutrophils with BAPTA/AM, an
intracellular Caz+ chelator, blocked degranulation but not
transmigration. Also the shedding of LAM-1 was not blocked
(Kuijpers et al., 1992) . Thus, degranulation is not necessar-
ily involved in diapedesis.
In conclusion, the migration of neutrophils across
monolayers of activated EC (shortly prestimulated with rIL-
10 or rTNFci) is mediated by an EC-associated form of PAF
in combination with IL-8 generated by EC. The down-
modulation of LAM-1 and CD44 during diapedesis may be
the result of this process.
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